Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $337.1 million.

  • Cidara Therapeutics' Cash from Financing Activities rose 187.91% to $160,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $481.8 million, marking a year-over-year increase of 101.72%. This contributed to the annual value of $337.1 million for FY2024, which is 1197.19% up from last year.
  • Cidara Therapeutics' Cash from Financing Activities amounted to $337.1 million in FY2024, which was up 1,197.19% from $26.0 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Cash from Financing Activities ranged from a high of $337.1 million in FY2024 and a low of -$951,000 during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $26.0 million (2023), whereas its average is $120.7 million.
  • In the last 5 years, Cidara Therapeutics' Cash from Financing Activities slumped by 102.13% in 2022 and then spiked by 2,832.28% in 2023.
  • Cidara Therapeutics' Cash from Financing Activities (Yearly) stood at $37.3 million in 2020, then increased by 19.63% to $44.6 million in 2021, then crashed by 102.13% to -$951,000 in 2022, then surged by 2,832.28% to $26.0 million in 2023, then spiked by 1,197.19% to $337.1 million in 2024.